Federal Register / Vol. 73, No. 15 / Wednesday, January 23, 2008 / Notices 3977 

the Secretary would review whether the 

software was interoperable, as defined 

in the regulations. The Secretary would 

consider the prevailing state of 

technology at the time the items or 

services were provided to the recipient. 

As explained in the regulations, the 

Secretary understands that parties 

should have a reasonable basis for 

determining whether the EHR software 

is interoperable. We therefore indicated 

that ‘‘it would be appropriate—and, 

indeed, advisable—for parties to consult 

any standards and criteria related to 

interoperability recognized by the 

Department.’’

Compliance with these standards and 

criteria, as we explained in the 

regulations, ‘‘will provide greater 

certainty to donors and recipients that 

products meet the interoperability 

requirement, and may be relevant in an 

enforcement action.’’

Based on the changing nature of 

technological development noted above, 

the Secretary has accepted and 

recognized these Interoperability 

Specifications. He has also delegated 

authority to ONC to coordinate and 

oversee the incorporation of these 

Interoperability Specifications in 

relevant activities among Federal 

agencies and other partner 

organizations, as appropriate. 

FOR FURTHER INFORMATION CONTACT: 

Judith Sparrow at (202) 690–7151. 

Dated: January 17, 2008. 

Robert M. Kolodner, 

National Coordinator for Health Information 

Technology, Office of the National 

Coordinator for Health Information 

Technology. 

[FR Doc. 08–234 Filed 1–17–08; 1:18pm] 

BILLING CODE 4150–45–P 

DEPARTMENT OF HEALTH AND 

HUMAN SERVICES 

Centers for Disease Control and 

Prevention 

[30Day–08–05CZ] 

Agency Forms Undergoing Paperwork 

Reduction Act Review 

The Centers for Disease Control and 

Prevention (CDC) publishes a list of 

information collection requests under 

review by the Office of Management and 

Budget (OMB) in compliance with the 

Paperwork Reduction Act (44 U.S.C. 

Chapter 35). To request a copy of these 

requests, call the CDC Reports Clearance 

Officer at (404) 639–5960 or send an email to omb@cdc.gov. Send written 

comments to CDC Desk Officer, Office of 

Management and Budget, Washington, 

DC or by fax to (202) 395–6974. Written 

comments should be received within 30 

days of this notice. 

Proposed Project 

Assessing the Diabetes Detection 

Initiative for Policy Decisions—New—

National Center for Chronic Disease 

Prevention and Health Promotion 

(NCCDPHP), Centers for Disease Control 

and Prevention (CDC). 

Background and Brief Description 

Type II diabetes is a chronic disease 

that affects more than 18 million 

Americans, approximately 5 million of 

whom do not know that they have the 

disease. As the disease progresses, it 

often causes severe complications, 

including heart disease, blindness, 

lower extremity arterial disease, and 

kidney failure. American Indians, 

African Americans, Latino Americans, 

and some Asian Americans and Pacific 

Islanders are disproportionately affected 

by diabetes. Identifying persons who 

have undiagnosed diabetes and treating 

them could prevent or delay diabetes 

complications. 

In November 2003 the Diabetes 

Detection Initiative (DDI) was launched 

in 10 regional locations around the U.S. 

to identify a portion of the estimated 5 

million people with undiagnosed Type 

II diabetes. The DDI was designed to 

refer persons at increased risk of Type 

II diabetes to diagnostic testing, and if 

appropriate, to follow-up treatment. 

Whether or not the DDI should be 

expanded to other communities 

depends on the health benefit and costs 

of the program. The CDC plans to 

conduct a one-year study to provide this 

critical information. 

The planned information collection 

will assess the resources used, the cost 

per case detected, and the perceived 

benefit of the DDI to patients. 

Information for the assessment will be 

obtained by conducting the following 

surveys: (1) A health clinic leadership 

survey will be completed by the clinic 

director or representative of each of the 

43 clinics that participated in the DDI. 

The survey will obtain information on 

all activities and resources used at the 

clinic level related to diabetes 

screening, detection, and outreach 

services. Approximately 30 of the 43 

eligible clinics are expected to 

participate in the survey. (2) A patient 

survey will be administered to a sample 

of 600 patients from the participating 

clinics. The survey will collect 

information about each patient’s 

background and out-of-pocket medical 

and non-medical direct health care costs 

(e.g., co-payments, transportation costs, 

and the value of the patient’s time 

associated with clinic visits). The DDI 

Patient Survey will include a computerassisted personal interview (CAPI) 

module to collect information about 

each patient’s stated preferences with 

respect to diabetes screening options. 

The results of the study will also 

provide information needed for 

evaluating the long-term costeffectiveness of screening for 

undiagnosed diabetes in the United 

States. 

There are no costs to the respondents 

other than their time. The total 

estimated annualized burden hours are 

263. 

ESTIMATED ANNUALIZED BURDEN HOURS

Type of 

respondents Form name Number of respondents 

Number of 

responses 

per 

respondent 

Average 

burden 

(in hours) 

DDI Clinic Representatives ................. DDI Health Clinic Leadership Survey .............................. 30 1 1 

Patients at DDI Clinics ........................ Screening Questions for the DDI Patient Survey ............ 1,000 1 2/60 

DDI Patient Survey ........................................................... 600 1 20/60 


ebenthall on PROD1PC69 with NOTICES
3978 Federal Register / Vol. 73, No. 15 / Wednesday, January 23, 2008 / Notices 

Dated: January 10, 2008. 

Maryam I. Daneshvar, 

Acting Reports Clearance Officer, Centers for 

Disease Control and Prevention. 

[FR Doc. E8–1016 Filed 1–22–08; 8:45 am] 

BILLING CODE 4163–18–P 

DEPARTMENT OF HEALTH AND 

HUMAN SERVICES 

Centers for Disease Control and 

Prevention 

[30Day–08–06AP] 

Agency Forms Undergoing Paperwork 

Reduction Act Review 

The Centers for Disease Control and 

Prevention (CDC) publishes a list of 

information collection requests under 

review by the Office of Management and 

Budget (OMB) in compliance with the 

Paperwork Reduction Act (44 U.S.C. 

Chapter 35). To request a copy of these 

requests, call the CDC Reports Clearance 

Officer at (404) 639–5960 or send an email to omb@cdc.gov. Send written 

comments to CDC Desk Officer, Office of 

Management and Budget, Washington, 

DC or by fax to (202) 395–6974. Written 

comments should be received within 30 

days of this notice. 

Proposed Project 

Aerosol Generation by Cough—

NEW—The National Institute for 

Occupational Safety and Health 

(NIOSH), Centers for Disease Control 

and Prevention (CDC). 

Background and Brief Description 

The National Institute for 

Occupational Safety and Health 

(NIOSH) is authorized to conduct 

research to advance the health and 

safety of workers under Section 20(a)(1) 

of the 1970 Occupational Safety and 

Health Act. 

Many respiratory diseases are spread 

when healthy people come into contact 

with infectious fluids from sick 

individuals. The most common mode of 

transmission is direct contact with 

infected persons, or contact with items 

or people they have touched. In 

addition, however, some respiratory 

illnesses can also spread via infectious 

aerosols that are generated by coughing 

and sneezing. Riley et al. established 

that tuberculosis is spread by inhalation 

of respirable particles generated by 

infected individuals. British studies of 

classrooms and offices found aerosols 

containing viable salivary streptococci 

and other oral bacteria that were 

thought to be created during speaking, 

coughing, and sneezing. Severe acute 

respiratory syndrome (SARS) and avian 

influenza are known to spread through 

infectious aerosols, and this may 

include cough-generated aerosols as 

well. 

The airborne transmission of disease 

is of great concern to the public health 

community because of the increasing 

prevalence of drug-resistant strains of 

tuberculosis, the epidemic potential of 

newly-emerging diseases like avian 

influenza, and the threat of bioterrorism 

using agents such as bubonic plague. 

The purpose of this project is to better 

understand some of the factors involved 

in the production of aerosols of airway 

fluids by coughing. The project has two 

specific aims: Measure the quantity and 

size distribution of aerosol produced 

during human coughs and determine 

the effectiveness of surgical masks and 

N95 respirators at filtering coughgenerated aerosols. 

There is no cost to respondents other 

than their time. The total estimated 

annualized burden hours are 71. 

ESTIMATED ANNUALIZED BURDEN HOURS

Type of 

respondent Form Number of respondents 

Number of 

responses 

per 

respondent 

Average 

burden 

per response 

(in hours) 

All participants .................................... Pre-test questionnaire ...................................................... 147 1 5/60 

Qualified participants .......................... Health questionnaire ........................................................ 140 1 5/60 

Consent form .................................................................... 140 1 20/60 

Dated: January 10, 2008. 

Maryam Daneshvar, 

Acting Reports Clearance Officer, Centers for 

Disease Control and Prevention. 

[FR Doc. E8–1017 Filed 1–22–08; 8:45 am] 

BILLING CODE 4163–18–P 

DEPARTMENT OF HEALTH AND 

HUMAN SERVICES 

National Institutes of Health 

Center for Scientific Review; Amended 

Notice of Meeting 

Notice is hereby given of a change in 

the meeting of the Center for Scientific 

Review Special Emphasis Panel, 

February 13, 2008, 1 p.m. to February 

13, 2008, 4:30 p.m., National Institutes 

of Health, 6701 Rockledge Drive, 

Bethesda, MD, 20892 which was 

published in the Federal Register on 

January 9, 2008, 73 FR 1634–1637. 

The meeting will be held February 14, 

2008. The meeting time and location 

remains the same. The meeting is closed 

to the public. 

Dated: January 15, 2008. 

Jennifer Spaeth, 

Director, Office of Federal Advisory 

Committee Policy. 

[FR Doc. 08–219 Filed 1–22–08; 8:45 am] 

BILLING CODE 4140–01–M 

DEPARTMENT OF HEALTH AND 

HUMAN SERVICES 

National Institutes of Health 

Center for Scientific Review; Notice of 

Closed Meetings 

Pursuant to section 10(d) of the 

Federal Advisory Committee Act, as 

amended (5 U.S.C. Appendix 2), notice 

is hereby given of the following 

meetings. 

The meetings will be closed to the 

public in accordance with the 

provisions set forth in sections 

552b(c)(4) and 552b(c)(6), Title 5 U.S.C., 

as amended. The grant applications and 

the discussions could disclose 

confidential trade secrets or commercial 

property such as patentable material, 

and personal information concerning 

individuals associated with the grant 

applications, the disclosure of which 

would constitute a clearly unwarranted 

invasion of personal privacy. 

Name of Committee: Biology of 

Development and Aging Integrated Review 

Group, Cellular Mechanisms in Aging and 

Development Study Section. 

Date: February 5–6, 2008. 

Time: 8 a.m. to 5 p.m. 

Agenda: To review and evaluate grant 

applications. 

Place: Sir Francis Drake Hotel, Kimpton, 

450 Powell Street, San Francisco, CA 94102. 

Contact Person: James P. Harwood, PhD, 

Scientific Review Administrator, Center for 

Scientific Review, National Institutes of 


ebenthall on PROD1PC69 with NOTICES